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Perua b s t r a c t
Self-medication impacts both negatively and positively the health of people, which has become evident
during the COVID-19 pandemic. The study aimed to assess the prevalence of self-medicated drugs used
for respiratory symptoms, as COVID-19 preventive, for its symptoms or once tested positive. To deter-
mine the perception of symptom relief and demographic variables that promote self-medication in
Peru. We performed a cross-sectional, analytical, multicenter study in 3792 study respondents on the
use, the reason for use, and perception of relief after the use of six drugs during the quarantine period.
An online questionnaire was developed, pretested and submitted to the general public. Multivariable
logistic regression was used to ascertain factors that influence an individual’s desire to self-medicate,
associations were considered significant at p < 0.05 and using region (coast, mountain and jungle) as clus-
ter group. The majority of respondents self-medicated with acetaminophen for respiratory symptoms
and mainly because they had a cold or flu. It was observed that all the surveyed drugs (acetaminophen,
ibuprofen, azithromycin, penicillin, antiretrovirals and hydroxychloroquine) were consumed for various
symptoms including: fever, fatigue, cough, sneezing, muscle pain, nasal congestion, sore throat, headache
and breathing difficulty. Over 90% of respondents perceived relief of at least one symptom. Multivariable
logistic regression showed that older people have a higher frequency of antiretroviral self-medication,
respondents who currently have a job had a higher frequency of penicillin self-medication, and that
respondents from the Andes consumed less acetaminophen, while the ones from the rainforest consumed
it more. There were significant percentages of self-medication, including drugs without sufficient scien-
tific evidence. Age, region where one lived and job status were variables associated with self-medication
frequency. Continuous awareness and sensitization about the risks of self-medication are warranted.
 2020 Published by Elsevier B.V. on behalf of King Saud University. This is anopenaccess article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The COVID-19 pandemic has triggered a general lock-down in
most of the world, leaving the general sense that the only resource
that people has is to self-help, self-care and self-medicate (Matias
et al., 2020). The latter gets worsened with the infodemic of fake
news that accompanied the COVID-19 pandemic (Tasnim et al.,
2020; Alvarez-Risco et al., 2020), and the vast exposure in the news
related to any study (in vitro, pre-clinical or clinical) that sheds
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2020). This has resulted in the self-medication of various
prescription drugs that have no confirmed clinical efficacy against
SARS-CoV-2 (Mallhi et al., 2020). Some of them include the anti-
malaria drug hydroxychloroquine (Hasan et al., 2020), the antibi-
otic azithromycin (Molina et al., 2020), the non-steroidal
anti-inflammatory drug (NSAID) ibuprofen (Sodhi et al., 2020)
and the antiretrovirals lopinavir and ritonavir (Lim et al., 2020).
Because of the lack of monitoring, these drugs could cause a
shortage of these drugs for patients that need them for approved
conditions (Jaffe, 2020), a direct impact in the price of these drugs
(Busari et al., 2020), and jeopardize peoples’ health due to their
known adverse events (Mallhi et al., 2020; Rojas et al., 2020).
Peru is among the top 5 countries in the world in reported
COVID-19 cases, and second in Latin America, only after Brazil
(Dong et al., 2020a). On September 20, 2020 Peru reported
768,895 COVID-19 cases with a 4.08% lethality rate (MINSA,
2020d). As Peru becomes a new epicenter of the pandemic in Latin
America multiple publications have illustrated its fragmented
healthcare system, which has not been the most effective during
the COVID-19 pandemic resulting in a high number of physicians’
deaths (Gonzales-Tamayo et al., 2020b) and detrimental effects in
the mental status of healthcare workers (Yáñez et al., 2020e). Fur-
thermore, Peru has reported discrepancies in the official reports of
COVID-19 deaths nationwide (Yáñez et al., 2020c), poor execution
of SARS-CoV-2 testing and reporting (Yáñez et al., 2020b), and an
increase number of COVID-19 cases in children and adolescents
(Yáñez et al., 2020a, Yáñez et al., 2020d). The Ministry of Health
in Peru was prompt in publishing COVID-19 symptomatic pharma-
cological treatment options to try to control de pandemic (MINSA,
2020c). This included the use in the clinical setting of hydroxy-
chloroquine and ivermectin for mild COVID-19 cases; and hydrox-
ychloroquine plus azithromycin and/or chloroquine phosphate
plus ivermectin for moderate and severe COVID-19 cases (MINSA,
2020c, Rojas et al., 2020). It comes as no surprise that self-
medication has become common in Peru as panic became general-
ized among the general public who is anxiously waiting for any
positive news regarding the prevention and treatment of this viral
infection. This becomes aggravated since Peru occupies the fifth
place in the world for COVID-19 confirmed cases (Dong et al.,
2020a), and it currently is the country with the highest mortality
rate (MenaFN, 2020).
This self-medication trend has been reported to have increased
worldwide based in the number of Google searches since the pan-
demic started (Onchonga, 2020). This global trend has caused a
tremendous medical challenge (Hughes et al., 2001; Mandal, 2015)
because the various prescription drugs currently approved for
COVID-19 symptoms carry adverse drug reactions (Onchonga
et al., 2020). Furthermore, there is high risk of incorrect dosage,
improper route of administration, longer use than intended, impro-
per storage, risk of dependency to abuse, and increasedprevalenceof
pathogenic resistance to drugs (Onchonga et al., 2020,Menary et al.,
2011). Even though, self-medication intention is common world-
wide it has only been reported in South Arabia (Mansuri et al.,
2020) and Kenya (Onchonga et al., 2020). However, these studies
assessed the prevalence of self-medication but did not surveyed
what drugs where actually consumed. In this way, we designed this
cross-sectional study to investigate the pattern of self-medication
among the general public in Peru during the COVID-19 pandemic.
The objectives of this study were to assess the prevalence of self-
medicated drugs used for respiratory symptoms, as COVID-19 pre-
ventive, for its symptoms or once tested positive. To determine the
perception of symptom relief and if there are any demographic vari-
ables that promote self-medication in Peru. The results would
informhealthcare policymakers on themeasures to improve in Peru
as they strive to save lives.2
2. Methods
2.1. Study design
We conducted an online cross-sectional multicenter survey,
which was initially evaluated by experts from different provinces
of Peru based on the Delphi method (Varela-Ruiz et al., 2012). After
including the experts’ observations, a pilot study was performed
(from May 25 to June 3) with 480 respondents in all the 25 pro-
vinces of Peru. The pilot data was used to calculate the minimum
sample size necessary for the actual study. It was determined that
a minimum sample size of 3,138 was necessary to achieve a min-
imum percentage difference of 2.5% (49.0% versus 51.5%), a statis-
tical power of 80%, and a confidence level of 95% (data not shown).
The sample size was calculated using power analysis (Walker et al.,
2017).
The actual survey consisted of an online questionnaire in Goo-
gle surveys that was sent via WhatsApp, Messenger, and Facebook,
and it was configured to submit an email at the end of the survey
so that investigation group can eliminate duplicate answers. The
shared questionnaire was made anonymous ensuring data confi-
dentiality and reliability. This survey was shared in Spanish, as this
is the official language in Peru. The survey was performed from
June 5 to 17 after approximately 3 months of lockdown and social
distancing measures in Peru due to the COVID-19 outbreak. At the
beginning of the survey (June 5) the number of COVID-19 con-
firmed cases was 187,400 and 5,162 deaths (MINSA, 2020a), while
at the end of the survey (June 17) the confirmed cases increased to
240,908 and the deaths increased to 7,257 (MINSA, 2020b). We
surveyed general public who were adults (over 18 years old) in
the 25 Peruvian provinces. Participants were recruited through
the COVID-19-GIS-Peru network. Grupo de Investigación en Salud
(GIS) stands for Health Research Group, a network of investigators
that include physicians, health professionals and students per-
forming COVID-19 social epidemiological studies in Peru and Lati-
namerica (Mejia et al., 2020a; Mejia et al., 2020b; Mejia et al.,
2020c; Mejia et al., 2020d; Mejia et al., 2020e; Araujo-Banchon
et al., 2020; Yáñez et al., 2020c).2.2. Outcomes and covariates
The survey (Annex 1) included 11 questions, 7 were demo-
graphic questions and 4 questions related to self-medication of
drugs to prevent and treat respiratory symptoms: drug selection,
reasoning for self-medication, symptoms they were looking to
improve, and if any of the drugs improved those symptoms. The
demographic questions included city where they live, gender,
age, marital status, education level, job status, and type of job.
The respondents were asked to indicate if during the COVID-19
lockdown they consumed any of the following drugs: acetamino-
phen, ibuprofen, azithromycin, hydroxychloroquine, penicillin,
antiretrovirals (lopinavir, ritonavir, remdesivir, and others), or
any other drug (open question) for respiratory symptoms. The
selection of drugs was based on the COVID-19 symptom treatment
options approved in Peru at the time (MINSA, 2020c) and based on
the drugs reported by the media to be viable treatment options.
The respondents were asked to select the reason to use of these
drugs from a 7-item list that included: had a cold/flu, no symp-
toms, COVID-19 prevention, had COVID-19 symptoms, COVID-19
positive, consume the drug regularly, other reason (open question).
The respondents were then presented with an 11-item list that
included the most common COVID-19 symptoms reported by the
Center of Disease Control and Prevention (CDC) (CDC, 2020). The
respondents were asked to select the symptom(s) why they con-
sumed any of the drug(s) indicated on the previous question. The
Table 1
Socio-demographic characteristics of respondents
during the COVID-19 lockdown in Peru.
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gestion, sore throat, headache, breathing difficulty. Sneezing was
included since it is a usual cold or flu symptom that often gets con-
fused with a COVID-19 symptom. No symptom and other symptom
(open question) was also included. Loss of taste or smell, nausea/
vomiting and diarrhea were not included. Loss of smell (anosmia)
was still debated as a COVID-19 symptom at the time of the prepa-
ration of the survey. Even though anosmia was reported in some
COVID-19 patients as early as April, it is until June 2020 when con-
crete scientific reports and reviews were published (Meng et al.,
2020).
Finally, the respondents were asked to indicate any symptom
improvement after drug intake using the 5-item Likert scale with
the following options: improved all symptoms, improved most of
the symptoms, improved a few of the symptoms, improved only
one symptom, did not alleviate any of the symptoms.
2.3. Statistical analysis
Data analysis was done in STATA version 14 (Stata Corp) with a
significance level set at p < 0.05. The instrument consistency was
assessed using the Kuder–Richardson Formula 20 (KR-20)
(Tschannen et al., 2020) for the dichotomous variable of either
using (or not) any of the assessed drugs during the lockdown in
Peru. The instrument validity was assessed with the known-
groups validity approach by fitting multivariate analysis (Jones
et al., 2018) to estimate the preference of self-medication for the
surveyed drugs using sex, age, marital status, job status, educa-
tional status, and region as control variables. Univariate statistics
was performed using frequencies and percentages for categorical
variables. For analytical statistics, adjusted prevalence ratios
(aPR) and 95% confidence intervals (CI) were obtained using gener-
alized linear models (GLM), with Poisson family, log-link function,
robust models and using region (coast, mountain and jungle) as
cluster group.
Peru gets divided into three geographic regions because the
Andes Mountains, these regions are the Coast (Costa), the Peruvian
Andes (Sierra), and the Jungle (Selva) (WHO, 2013). This geograph-
ical division is accompanied with marked differences in access,
roads, urbanization, population distribution, health and education
services. This results in marked differences in health conditions
with the coast, Andes and rainforest having the under-5 mortality
rate at 26%, 39% and 42%, respectively (WHO, 2013). This is in part
due to different behaviors toward urgency for medical treatment
and the prevalence of pharmacological use. In order to assess dif-
ferences in our study we used region as a cluster group.
2.4. Ethical approval
The survey was approved by the Universidad Privada Antenor
Orrego ethics committee (#0209–2020-UPAO). The participants
remained anonymous and had the option to finish the survey at
any time, and their information was kept confidential. All the sur-
vey participants were well-versed on the study intentions and
were required to consent before the enrollment. The participants
were not involved in any of the planning, execution and reporting
stages of the study.Housekeeper 19 (1.6)
Entertainment 13 (1.1)






a Median and interquartile range.3. Results
3.1. Sociodemographic characteristics of the respondents
The survey was sent to 6,000 people in the 25 provinces of Peru
in order to achieve the minimum sample size of 3,138 calculated
based on power analysis. Out of the 6,000 surveys sent online,3
we received 3,792 responses indicating a 63.2% response rate. Most
participants were female (2066 [54.5%]), aged 18 to 85 years, single
(3046 [80.3%]), had a bachelor degree or higher (2850 [75.2%]), had
a job (1219 [32.1%]) and the predominant job industry was health-
care (315 [25.8%]) as shown in Table 1. The obtained KR-20 values
for the dichotomous variable of either using (or not) any of the
assessed drugs during the lockdown in Peru was > 0.7.
3.2. Non COVID-19 related reasons for self-medication
As shown on Table 2, the majority of respondents did not self-
medicate (2526 [66.6%]) with any of the surveyed drugs (ac-
etaminophen, ibuprofen, azithromycin, hydroxychloroquine, peni-
cillin or azithromycin). Out of the 3792 respondents, it was
observed that 1023 respondents reported that they consumed
acetaminophen during lockdown, while 281 consumed ibuprofen,
182 azithromycin, 87 penicillin, 60 antiretrovirals and 28 hydrox-
ychloroquine. For all the drugs the main reason for consumption
was because the person reported they had a cold or flu. It was
observed that a portion of respondents self-medicated because
other reasons. For instance, 178 and 75 respondents consumed
acetaminophen and ibuprofen, respectively for other reasons,
which could be attributed to their broad use as pain relievers
and antipyretics. Similarly, for the antibiotics azithromycin and
penicillin it was reported that 16 and 28 people, respectively con-
sumed them for other reasons. To a lower extent it was reported
that 2 people used the anti-malarial drug hydroxychloroquine for
other reasons. We also surveyed if these drugs were consumed reg-
ularly, and it was observed that 76 people consumed acetamino-
phen, 26 ibuprofen, 15 azithromycin, 6 penicillin, 5
antiretrovirals and 3 hydroxychloroquine. Even more concerning,
was to observe that people in Peru consumed these drugs without
any symptom. For instance, 17 consumed acetaminophen, 7
ibuprofen, 3 azithromycin, 2 hydroxychloroquine, 1 penicillin
Table 2
Self-medication, reason and respiratory symptom improvement with various drugs during the COVID-19 lockdown in Peru.
Variables Acetaminophen Ibuprofen Azithromycin Hydroxychloroquine Penicillin Antiretrovirals
Use during lockdown
Yes 1023 (27.0%) 282 (7.4%) 182 (4.8%) 28 (0.7%) 87 (2.3%) 60 (1.6%)
No 2769 (73.0%) 3510 (92.6%) 3610 (95.2%) 3764 (99.3%) 3705 (97.7%) 3732 (98.4%)
Reason
Cold or flu 675 (66.0%) 162 (57.6%) 98 (53.9%) 14 (50.0%) 60 (68.9%) 41 (68.3%)
No symptoms 17 (1.7%) 7 (2.5%) 3 (1.7%) 2 (7.2%) 1 (1.2%) 1 (1.7%)
COVID-19 preventive 6 (0.6%) 1 (0.4%) 7 (3.9%) 3 (10.7%) 2 (2.3%) 4 (6.7%)
COVID-19 symptoms 65 (5.4%) 9 (3.2%) 23 (12.6%) 1 (3.6%) 1 (1.2%) 3 (5.0%)
COVID-19 positive 6 (0.6%) 1 (0.4%) 8 (4.4%) 3 (10.7%) 1 (1.2%) 1 (1.7%)
Consume it regularly 76 (7.4%) 26 (9.2%) 15 (8.2%) 3 (10.7%) 6 (6.9%) 5 (8.3%)
Other reason 178 (17.3%) 75 (26.7%) 28 (15.4%) 2 (7.1%) 16 (18.3%) 5 (8.3%)
Symptom improvement
All symptoms improved 482 (47.1%) 136 (48.4%) 79 (43.4%) 12 (42.9%) 41 (47.1%) 36 (60.0%)
Many symptoms improved 287 (28.0%) 66 (23.5%) 56 (30.8%) 7 (25.0%) 30 (34.5%) 18 (30.0%)
Some symptoms improved 96 (9.4%) 34 (12.1%) 27 (14.8%) 6 (21.4%) 6 (6.9%) 5 (8.3%)
One symptom improved 135 (13.2%) 34 (12.1%) 11 (6.0%) 1 (3.6%) 7 (8.0%) 0 (0.0%)
No improvement 23 (2.3%) 11 (3.9%) 9 (5.0%) 2 (7.1%) 3 (3.5%) 1 (1.7%)
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the same respondent could have used more than one drug at the
same time.
3.3. COVID-19 related reasons for self-medication
On our survey we included three reasons for drug use related to
COVID-19: as a preventive, presence of symptoms, and confirmed
case. When these three reasons were combined it was observed
that the drug with the highest self-medication was acetaminophen
with 77 respondents, azithromycin (38), ibuprofen (11), antiretro-
virals (8), hydroxychloroquine (7) and penicillin (4). It was
observed that as a COVID-19 preventive, 7 respondents self-
medicated with azithromycin, 6 with acetaminophen, 4 with
antiretrovirals, 3 with hydroxychloroquine, 2 with penicillin and
1 with ibuprofen. When COVID-19 symptoms were present, the
trend changed with acetaminophen been the drug with the highest
self-medication (65), followed by azithromycin (23), ibuprofen (9),
antiretrovirals (3), hydroxychloroquine (1) and penicillin (1). We
also surveyed the self-medication use when diagnosed as COVID-
19 positive and it was observed that 8 people used azithromycin,
6 acetaminophen, 3 hydroxychloroquine, and 1 person for ibupro-
fen, penicillin and antiretrovirals (Table 2).
3.4. Respiratory symptoms attributed to self-medication
Fig. 1 shows the distribution of respiratory symptoms for which
the respondents self-medicated with the various drugs we sur-
veyed. The respiratory symptoms we surveyed for were fever, fati-
gue, cough, sneezing, muscle pain, nasal congestion, sore throat,
headache and breathing difficulty. We also surveyed if the respon-
dents self-medicated without any symptom. It was observed that
for all the symptoms, except breathing difficulty, the most self-
medicated drug was acetaminophen. In the case of fever, 568
respondents indicated that they consumed at least one of the drugs
we surveyed for. For fatigue 145 respondents, 273 for cough, 323
for sneezing, 368 for muscle pain, 291 for nasal congestion, 488
for sore throat, 707 for headache, 60 for breathing difficulty, and
119 without any symptom. In the case of fever, the predominant
drugs consumed were acetaminophen (404 [71%]) followed by
ibuprofen (74 [13%]). For fatigue, 80 (55.2%) used acetaminophen
followed by ibuprofen 24 (16.6%); for cough 137 (50.2%) consumed
acetaminophen and 46 (16.8%) azithromycin. In the case of sneez-
ing, often confused as a COVID-19 symptom, the most used drug
for this symptom was acetaminophen (188 [58.2%]) followed by
azithromycin (46 [14.2%]). For muscle pain the most consumed4
drugs were the analgesics acetaminophen (235 [63.8%]) and
ibuprofen (82 [22.3%]), similar situation was observed for sore
throat: acetaminophen (259 [53.1%]) and ibuprofen (93 [19.1%])
and for headache: acetaminophen (561 [79.3%]) and ibuprofen
(97 [13.7%]). For nasal congestion, 166 (57.0%) used acetamino-
phen and 49 (16.8%) azithromycin; while for breathing difficulty
22 (36.7%) used azithromycin and 17 (28.3%) acetaminophen. It
became alarming that 119 respondents consumed the surveyed
drugs without any symptom with the following distribution: acet-
aminophen (36 [30.3%]), ibuprofen (36 [30.3%]), azithromycin (22
[18.5%]), penicillin (12 [10.1%]), antiretrovirals (8 [6.7%]) and
hydroxychloroquine (5 [10.1%])
3.5. Perception of symptom improvement after self-medication
The majority of respondents indicated that they perceived that
at least one symptom improved with the use of acetaminophen
(1000 [97.7%]), ibuprofen (270 [96.1%]), azithromycin (173
[95.0%]), penicillin (84 [96.5%]), antiretrovirals (59 [98.3%]) and
hydroxychloroquine (26 [92.9%]) (Table 2). However, this could
have been attributed to the combined use of more than one of
these drugs or the combination of other drugs that were not
assessed in this study. It was observed that a portion of respon-
dents self-medicated because other reasons, which could be attrib-
uted to the broad application of the surveyed drugs. For instance,
acetaminophen and ibuprofen are widely used as pain relievers
and antipyretics. Similarly, azithromycin and penicillin are antibi-
otics that are consumed for various conditions, and in the case of
the anti-malarial drug hydroxychloroquine is also used for lupus
and rheumatoid arthritis (Jaffe, 2020).
The respondents had the option to indicate any other drug that
they used for respiratory symptoms and various drug classes were
reported such as antihistamines (cetirizine, chlorphenamine, lora-
tadine), nonsteroidal anti-inflammatory drugs (NSAIDs) (naproxen,
diclofenac), antibiotics (amoxicillin), corticosteroids (dexametha-
sone), analgesics (metamizole), flu medicine (not specified), vita-
min supplements (vitamin C), and others (ginger, garlic, honey,
onion, lemon, eucalyptus and sodium bicarbonate). Regarding the
total responses for other drugs, the most frequent was cetirizine
(13%) followed by chlorphenamine (9%), and naproxen (7%).
3.6. Multivariate analysis of the factors prompting respondents to self-
medication
In the multivariate analysis (Table 3), it was observed that older
respondents had a higher frequency of antiretroviral self-
Fig. 1. Respiratory symptom distribution for self-medication of various drugs during the COVID-19 lockdown in Peru.
Table 3
Multivariate analysis of the factors associated with the self-medication of various drugs during the COVID-19 lockdown in Peru.
Variables Acetaminophen Ibuprofen Azithromycin Hydroxychloroquine Penicillin Antiretrovirals
Sex 0.574 0.988 0.911 0.433 0.299 0.563
Age (years)* 0.542 0.445 0.380 0.908 0.207 (+) 0.043
Single marital status 0.787 0.448 0.070 0.671 Not converge 0.175
Currently have a job 0.500 0.740 0.109 0.141 (+) 0.028 0.891
At least Bachelor’s degree 0.602 0.740 0.206 0.627 0.845 0.742
Region of Peru
Coast This category served as a comparison
Andes () 0.001 0.353 0.055 0.877 0.537 0.347
Rainforest (+) 0.012 0.146 0.992 Not converge Not converge Not converge
The dependent variable corresponds to the sum of respondents who used the drugs as a preventive, presence of symptoms, and confirmed case.
The reported p-values were obtained by generalized linear models, with the Poisson family, log link function, and robust models.
p-values < 0.05 have a sign that indicates whether there was a positive or negative association with the dependent variable.
* This variable was taken quantitatively.
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adjusted for gender, marital status, job status, and educational
level. It was also observed that respondents who currently have a
job had a higher frequency of penicillin self-medication (aPR:
8.86; 95% CI: 1.27–61-93; p-value: 0.028) when adjusted for gen-
der, age, marital status, and level of education. The region (coast,
Andes and rainforest) was used a cluster group with the consump-
tion of drugs in the coast used as the category for comparison. It
was observed that for acetaminophen, the respondents from the
Andes consumed it less (aPR: 0.47, 95% CI: 0.29–0.74, p-value:
0.001), while the respondents from the rainforest consumed more
acetaminophen (aPR: 2.68, 95% CI: 1.24–5.79, p-value: 0.012).
There were no other significant differences in consumption of the
other drugs between regions of Peru.4. Discussion
Self-medication is more common in countries where healthcare
systems tend to be less effective because of long waiting time in
healthcare facilities, difficulty in obtaining physicians’ appoint-
ments, insufficient stock of essential medicines, delay in attention5
and insufficient amount of available beds/space in healthcare facil-
ities (Meena et al., 2016). Even before the pandemic Peru already
reunited all these characteristics (Alvarez-Risco et al., 2016;
Alvarez-Risco et al., 2018), which became more evident during
the COVID-19 pandemic exposing Peru’s fragmented and under-
funded healthcare system (Gonzales-Tamayo et al., 2020a). Most
of the respondents in our study were healthcare workers that dur-
ing the lockdown have been the first respondents exposed to
higher risk of becoming infected with COVID-19 (Ing et al.,
2020). The long hours at work under difficult and stressful circum-
stances (Bogren et al., 2020) have caused an increase in anxiety,
distress and overall psychological burden in healthcare workers
in Peru (Yáñez et al., 2020e). These conditions have been reported
to trigger self-medication in order to face work-related stress, pres-
sure, discomfort and anxiety (Omolase et al., 2007; Barros et al.,
2009). The general public is also under stress, anxiety and distress
conditions as Peru reports a high number of physician deaths
because of COVID-19 (Gonzales-Tamayo et al., 2020a) and has
recently became the country with the highest mortality in the
world (MenaFN, 2020; Yáñez et al., 2020c).
Our study reported that acetaminophen was the drug most con-
sumed with higher use in the rainforest and lower in the Andes
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reported to be a drug that is preferentially self-medicated in Ethio-
pia (Shafie et al., 2018) and Brazil (Barros et al., 2019) for chronic
pain. It has been reported that acetaminophen is widely used by
health science major students in Nigeria as a pain reliever (Esan
et al., 2018). However, it is alarming that its consumption is
believed to be non-toxic regardless of the dose (Esan et al.,
2018). Acetaminophen standard therapeutic oral dose is 0.5–1 g
every 4–6 h to a maximum of 4 g/day, but more importantly it
has a dose-dependent toxicity (Roberts et al., 2016). Acetamino-
phen can cause hepatoxicity after major overdose (Prescott,
2000), and severe liver damage has been observed with long-
term use even at therapeutic doses in patients with alcoholic liver
disease or viral infections (Day et al., 2000). Furthermore, it has
been reported that long-term consumption of acetaminophen car-
ries a potential risk factor for chronic renal failure (McLaughlin
et al., 1998), cardiovascular, gastrointestinal and even mortality
(Roberts et al., 2016). Therefore, acetaminophen is a drug to con-
sume with caution especially considering that its sales has
increased significantly during the COVID-19 pandemic (Romano
et al., 2020).
Ibuprofen was the second drug most consumed (7.4%) in our
study even though it has been reported that this NSAID increases
the risk of developing thromboembolism in COVID-19 patients
(Arjomandi Rad et al., 2020). Furthermore, it has been proposed
that it could worsen the course of COVID-19 infection (Yang
et al., 2020; Favalli et al., 2020; Fang et al., 2020), but more evi-
dence is still needed (Torjesen, 2020). It also needs to considered
that ibuprofen alone or in combination with acetaminophen could
mask the fever during COVID-19 infection causing a delay in diag-
nosis and treatment (Favalli et al., 2020; Torjesen, 2020).
Regarding the consumption of the antibiotic azithromycin, one
in five respondents who consumed it reported that they consumed
it without having any respiratory symptom, as a preventive mea-
sure or because they thought they would have COVID-19. In an
in vitro study, the combination of azithromycin and hydroxy-
chloroquine showed a synergistic effect against SARS-CoV-2, and
it was also reported on the possible anti-inflammatory properties
of azithromycin, which could improve the disease progression
(Damle et al., 2020; Andreani et al., 2020). However, its administra-
tion in combination therapy with hydroxychloroquine has been
implicated in the elevation of the QT interval (Mercuro et al.,
2020). Given the limited data available to ensure the efficacy of
combination therapy, the American Society for Infectious Diseases
recommends that the hydroxychloroquine/ chloroquine plus azi-
thromycin combination be limited to clinical trials (Mercuro
et al., 2020; Bhimraj et al., 2020). Regarding the self-medication
of hydroxychloroquine, our study reported that one in four respon-
dents who consumed it said that it was without symptoms, as a
preventive measure or because they developed COVID-19 symp-
toms. The combined use of hydroxychloroquine and azithromycin
was publicly endorsed by President Trump, which caused self-
medication causing several reports of severe poisoning in Nigeria
and USA (Busari et al., 2020). This public endorsement triggered
various in vitro and in vivo studies that reported a decrease in viral
load and mitigation in the cytokine storm in critically ill patients
with SARS-CoV-2 (Gautret, Lagier, Parola, Hoang, Meddeb, Mailhe,
et al., 2020). Similarly, various studies reported the positive use of
hydroxychloroquine and azithromycin for treatment in hospital-
ized COVID-19 patients (Yao et al., 2020; Gautret et al., 2020a;
Gautret et al., 2020b; Million et al., 2020). However, the consump-
tion of hydroxychloroquine with or without azithromycin caused
an increase in cardiotoxic risk such as QT prolongation, torsades
de pointes, and sudden death in hospitalized patients with
COVID-19 (Mercuro et al., 2020; Chorin et al., 2020; Ramireddy
et al., 2020). Even though, the literature alerts about the possible6
risks with the combination of azithromycin and hydroxychloro-
quine it is recommended in Peru for moderate and severe
COVID-19 cases in a clinical setting since May 2020 (MINSA,
2020c, Rojas et al., 2020). For mild COVID-19 patients, hydroxy-
chloroquine is recommended at a dose of 400 mg orally every
12 h for the first day, and 200 mg orally every 12 h for 6 days
(MINSA, 2020c). In the case of moderate to severe COVID-19
patients, hydroxychloroquine is recommended at a dose of
200 mg orally every 8 h for 7 –10 days, or hydroxychloroquine
+ azithromycin at a dose regimen of 200 mg orally every 8 h for
7–10 days (hydroxychloroquine) + 500 mg orally on the first day
and then 250 mg every 24 h for 5 days (MINSA, 2020c). However,
on September 7, 2020 the ex-Minister of Health of Peru, Victor
Zamora requested for ivermectin, hydroxychloroquine and azithro-
mycin to be removed from the official COVID-19 treatment in Peru
(RPP, 2020). It was during his administration that their use was
approved, but his recent request was based on the lack of efficacy
and increased risk that has been observed over the last few months
(RPP, 2020).
Regarding the consumption of antiretrovirals, our study
reported that one in six respondents consumed them without
symptoms, as a preventive measure or because they thought they
had COVID-19. Our multivariate analysis indicated that older peo-
ple tend to have a higher consumption of antiretrovirals. This could
be caused because the perception that any antiretroviral would
have a positive effect against the viral COVID-19 infection. How-
ever, liver damage has been observed in COVID-19 patients
(Velarde-Ruiz Velasco et al., 2020). Considering that antiretrovirals
list liver damage as a common adverse effect (Alonso-Bello et al.,
2018; Mallolas et al., 2003), it would make them inappropriate
for use in COVID-19 patients. Their use is relevant for other
pathologies, but a recent review has determined that there is no
clear evidence of the beneficial effects of antiretrovirals in the pre-
vention of COVID-19 (Ford et al., 2020; Dong et al., 2020b). More
research is still needed to determine the cost and benefit of
antiretrovirals for COVID-19.
Our study reported that 19 people self-medicated with peni-
cillin without having symptoms, as a preventive measure or
because they thought they would have COVID-19. It becomes
interesting that penicillin was used because it lacks scientific infor-
mation that supports its use for COVID-19. However, its use could
be partially attributed to a lack of general knowledge about COVID-
19 symptoms (Gomez Tejeda et al., 2020) and lack of information
on what drugs to take (Huaroto et al., 2020). More research is
needed in order to determine the effect of penicillin in COVID-19
patients.
The respondents indicated that they perceived an improvement
in respiratory and COVID-19 symptoms after self-medication with
these drugs alone or in combination. However, this could have
been due to a placebo effect or because the symptoms were mild
or because the majority of COVID-19 patients recover due to its
lethality rate of less than 5% (MINSA, 2020d). Even though, some
of these drugs in Peru do not need prescription (acetaminophen
and ibuprofen), the others (azithromycin, hydroxychloroquine,
penicillin and antiretrovirals) require prescription. Therefore, the
pharmaceutical care system needs to be revised in Peru to prevent
people to obtaining prescription-drugs so easily or in the black
market. According to the World Health Organization (WHO)
(WHO, 2000), it is important in a healthcare system to provide per-
sonal assessment to patients during pharmaceutical care as an
important strategy to provide guidance in the use of Over-the-
counter (OTC) and prescription drugs (Tong et al., 2019).
The study had as a limitation that the results cannot be extrap-
olated to the entire Peruvian population since a random or multi-
level sampling has not been carried out for this purpose. Also,
cross-sectional studies do not permit an establishment of a clear
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quencies of use and find some statistical associations; however,
this report becomes the first study in such a large population in
Peru, which could serve as a basis for other research.5. Conclusion
Self-medication is a significant health issue in Peru, especially
during the COVID-19 pandemic. Various drugs were used for respi-
ratory and COVID-19 related symptoms without sufficient scien-
tific evidence. Acetaminophen was the most consumed drug, but
there was also a significant use of antibiotics (penicillin and azi-
thromycin), hydroxychloroquine, and even antiretrovirals. People
in Peru consumed them as COVID-19 preventives, to treat sus-
pected symptoms and even after a COVID-19 positive diagnosis.
Acetaminophen consumption was associated with the region
where one lived, antiretrovirals consumption was associated with
the age of the respondent, and penicillin consumption was higher
in people currently working. Continuous awareness and sensitiza-
tion about the risks of self-medication are warranted. Our results
should be taken with care and not interpreted as a recommenda-
tion to self-medicate nor to use these drugs thinking that they will
improve symptomatology. Always seek medical help and consulta-
tion before consuming any drug. We hope these results would
inform healthcare policy makers on the measures to improve phar-
maceutical care as they strive to save lives.7
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to influence the work reported in this paper.Annex 1. Survey to assess the use of drugs in the prevention and treatment of respiratory symptoms during the COVID-19 pandemic
Demographic data
1. City where you live: ______________________
2. Sex: Male () Female () I prefer not to say ()
3. Age: _________ (years)
4. Marital status: Single () Married () Domestic partnership () Divorced () Widowed ()
5. Education level: No studies () Primary () High School () Associate () Bachelor () Postgraduate ()
6. Do you currently work?
7. If you work, indicate the industry: Food () Commerce () Construction () Education () Housekeeper () Entertainment () Police/Armed
forces () Healthcare () Transportation () Tourism () Telecommunications () Other:____________
About the use of drugs against respiratory symptoms during the COVID-19 lockdown
8. Indicate if you use any of these drugs during the COVID-19 lockdownDrug Did you use it?Paracetamol / Acetaminophen Yes () No ()
Ibuprofen Yes () No ()
Azithromycin Yes () No ()
Hydroxychloroquine Yes () No ()
Penicillin Yes () No ()
Antiretroviral (Lopinavir, Ritonavir,
Remdesivir, etc.)
Yes () No ()Another drug (please specify) ______________ Yes () No ()
Jean Franco Quispe-Cañari, E. Fidel-Rosales, D. Manrique et al. Saudi Pharmaceutical Journal 29 (2021) 1–119. Indicate the reason why you used the drugs you did during the COVID-19 lockdown
The reasons are numbered from 1 to 7
1. I had a cold/flu
2. I used it without having any symptom
3. I used it as a preventive for COVID-19
4. I had COVID-19 symptoms and self-medicated
5. I was positively diagnosed with COVID-19 and self-medicated to treat it
6. I consumed it regularly because other reasons
7. Other (please specify)
Check only one option for each drug you usedDrug8
Why did you consume this drug?Paracetamol /
Acetaminophen1 () 2 () 3 () 4 () 5 () 6 () 7 ()Ibuprofen 1 () 2 () 3 () 4 () 5 () 6 () 7 ()
Azithromycin 1 () 2 () 3 () 4 () 5 () 6 () 7 ()
Hydroxychloroquine 1 () 2 () 3 () 4 () 5 () 6 () 7 ()
Penicillin 1 () 2 () 3 () 4 () 5 () 6 () 7 ()
Antiretroviral 1 () 2 () 3 () 4 () 5 () 6 () 7 ()
Another drug: _________ 1 () 2 () 3 () 4 () 5 () 6 () 7 ()10. Indicate the symptom(s) for which you use the drugs you did










10. I used this drug even though I did not have any of the previous symptoms
11. Other (please specify the symptom)
You can check more than one symptomDrug What symptom(s) did you use this drug for?Paracetamol / Acetaminophen 1 () 2 () 3 () 4 () 5 () 6 () 7 () 8 () 9 () 10 () 11 ()
Ibuprofen 1 () 2 () 3 () 4 () 5 () 6 () 7 () 8 () 9 () 10 () 11 ()
Azithromycin 1 () 2 () 3 () 4 () 5 () 6 () 7 () 8 () 9 () 10 () 11 ()
Hydroxychloroquine 1 () 2 () 3 () 4 () 5 () 6 () 7 () 8 () 9 () 10 () 11 ()
Penicillin 1 () 2 () 3 () 4 () 5 () 6 () 7 () 8 () 9 () 10 () 11 ()
Antiretroviral 1 () 2 () 3 () 4 () 5 () 6 () 7 () 8 () 9 () 10 () 11 ()
Another drug: ______________ 1 () 2 () 3 () 4 () 5 () 6 () 7 () 8 () 9 () 10 () 11 ()11. Indicate if you perceived the use of these drugs alleviated your symptoms
Options are numbered from 1 to 5
1. I perceive that it alleviated all the symptoms
2. I perceive that it alleviated most of the symptoms
3. I perceive that it alleviated a few of the symptoms
4. I perceive that it alleviated only one symptom
5. I perceive that it did not alleviated any of the symptoms
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Did this drug alleviated your symptoms?Paracetamol / Acetaminophen 1 () 2 () 3 () 4 () 5 ()
Ibuprofen 1 () 2 () 3 () 4 () 5 ()
Azithromycin 1 () 2 () 3 () 4 () 5 ()
Hydroxychloroquine 1 () 2 () 3 () 4 () 5 ()
Penicillin 1 () 2 () 3 () 4 () 5 ()
Antiretroviral 1 () 2 () 3 () 4 () 5 ()
Another drug: ______________ 1 () 2 () 3 () 4 () 5 ()References
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